Profil dan Karakteristik Penderita Tumor Trofoblas Gestasional di RSUP Dr. Hasan Sadikin Periode 2021

Muhamad Bagja Ramadhan; Siti Salima; Andi Kurniadi; Gatot Nyarumenteng Adhipurnawan Winarno; Ali Budi Harsono

doi:10.24198/obgynia/v5n2.380

Profil dan Karakteristik Penderita Tumor Trofoblas Gestasional di RSUP Dr. Hasan Sadikin Periode 2021

Muhamad Bagja Ramadhan,^(1*) Siti Salima,⁽²⁾ Andi Kurniadi,⁽³⁾ Gatot Nyarumenteng Adhipurnawan Winarno,⁽⁴⁾ Ali Budi Harsono,⁽⁵⁾

(1) Fakultas Kedokteran Universitas Padjadjaran
(2) Divisi Onkologi Ginekologi, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Padjadjaran/Rumah Sakit Umum Pusat Dr. Hasan Sadikin, Bandung
(3) Divisi Onkologi Ginekologi, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Padjadjaran/Rumah Sakit Umum Pusat Dr. Hasan Sadikin, Bandung
(4) Divisi Onkologi Ginekologi, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Padjadjaran/Rumah Sakit Umum Pusat Dr. Hasan Sadikin, Bandung
(5) Divisi Onkologi Ginekologi, Departemen Obstetri dan Ginekologi, Fakultas Kedokteran Universitas Padjadjaran/Rumah Sakit Umum Pusat Dr. Hasan Sadikin, Bandung
(*) Corresponding Author

Abstract

Tujuan: Tumor trofoblas gestasional (TTG) adalah suatu bentuk keganasan ginekologi pada hidatidosa yang diakibatkan oleh adanya abnormalitas proliferasi sel trofoblas. Insidensi TTG di negara Asia Tenggara ialah 9,2:40000 kehamilan. Beberapa faktor yang mempengaruhi perkembangan TTG diantaranya ialah riwayat kehamilan, usia dan kadar b-hcg. Namun hingga saat ini profil pasien TTG masih terbatas, oleh karenanya penelitian ini bertujuan menganalisis profil dan karakteristik pasien TTG di RSUP Dr. Hasan Sadikin Bandung.
Metode: Metode penelitian ini ialah deskriptif kuantitatif, dengan menggunakan data sekunder yang berasal dari rekam medis pasien. Seluruh pasien yang didiagnosis TTG pada periode 2021 menjadi sampel pada penelitian ini. Variabel penelitian ini ialah status sosiodemografi, faktor risiko, gambaran klinis, dan gambaran terapi.
Hasil: Jumlah sampel pada penelitian ini ialah 66 pasien. Sebanyak 53,03% pasien berusia 20-35 tahun. Sebanyak 55 pasien datang dalam kondisi stadium I (83,33%) sedangkan berdasarkan skoring FIGO sebanyak 42 pasien (63,63%) merupakan pasien dengan risiko rendah. Metastasis paru terjadi pada 7 pasien (20,61%).
Kesimpulan: Mayoritas pasien TTG berusia 20-35 tahun dan tidak bekerja. Secara gambaran klinis; stadium I dan risiko rendah sering ditemukan. Kemoterapi dominan dipilih, serta multi-agent lebih sering digunakan.

Profile and Characteristics GTN cases in Hasan Sadikin General Hospital in 2021 Gestational Trophoblastic Neoplasma

Abstract
Objective: Gestational trophoblastic tumor (TTG) is a form of hydatidiform gynecologic malignancy caused by abnormal trophoblast cell proliferation. The incidence of TTG in Southeast Asian countries is 9.2:40000 pregnancies. Several factors that influence the development of TTG include a history of pregnancy, age and levels of b-hCG. However, until now the profile of TTG patients is still limited, therefore this study aims to analyze the profiles of TTG patients at Dr. Hasan Sadikin Bandung.
Methods: This research method is descriptive quantitative, using secondary data derived from the patient's medical record. All patients diagnosed with TTG in the period 2021 were sampled in this study. The variables of this study were sociodemographic status, risk factors, clinical features, and therapeutic features.
Results: The number of samples in this study was 66 patients. A total of 53.03% of patients aged 20-35 years. A total of 55 patients came in stage I condition (83.33%) while based on FIGO scoring 42 patients (63.63%) were low risk patients. Pulmonary metastases occurred in 7 patients (20.61%).
Conclusion: The majority of TTG patients are aged 20-35 years and do not work. In the clinical picture; stage I and low risk are common. Predominant chemotherapy is chosen, and multi-agent is used more often.

Key words: Gestational Trophoblastic Neoplasia, Patient Profile, Hydatidiform mole, Gynecological Malignancy

Keywords

Tumor Trofoblas Gestasional; Kanker Ginekologi; Onkologi Ginekologi

Full Text:

PDF

References

Braga A, Mora P, Melo AC de, Nogueira-Rodrigues A, Amim-Junior J, Rezende-Filho J, et al. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide. World J Clin Oncol. 2019;10(2):28–37.

Jareemit N, Benjapibal M. Gestational trophoblastic neoplasia with gum metastasis: a case study and literature review. Case Rep Oncol. 2020;13:485–90.

Ning F, Hou H, Morse AN, Lash GE. Understanding and management of gestational trophoblastic disease [version 1; peer review: 2 approved]. F1000Research. 2019;8.

Huanca-Llamo J, Aranzabal-Alegria G, Chanduví W. Factors associated with gestational trophoblastic disease in a peruvian reference hospital. Rev la Fac Med Humana. 2020;20(1):64–9.

Vecchia C La, Franceschi S, Parazzini F, Fasoli M, Decarli A, Gallus G, et al. Risk factors for gestational trophoblastic disease in Italy. Am J Epidemiol. 1985;121(3):457–64.

Milani HS, Abdollahi M, Torbati S, Asbaghi T, Azargashb E. Risk factors for hydatidiform mole: Is husband’s job a major risk factor? Asian Pacific J Cancer Prev. 2017;18(10):2657–62.

Berek JS, Hacker NF, Hengst T. Gynecologic oncology. 6th ed. Elfrank JM, editor. Philadelphia: Wolters Kluwer; 2015. 625–648 p.

Rachdi H, Mokrani A, Batti R, Raies H, Touhami O, Ayadi M, et al. Gestational trophoblastic neoplasia: A Tunisian multicenter study. Asian Pacific J Cancer Care. 2019;4(2):59–64.

Randriamaroson N, Razakanaivo M, Andrianandrasana NO, Solofonirina ZA, Rafaramino F. Gestational trophoblastic neoplasia: clinical and therapeutic profile in Madagascar. Open J Obstet Gynecol. 2020;10:946–56.

Ngu S-F, Chan KKL. Management of Chemoresistant and Quiescent Gestational Trophoblastic Disease. Curr Obstet Gynecol Rep. 2014;3(1):84–90.

Aznab M, Nankali A, Daeichin S. Determination of clinical process and response rate to treatment in patients with gestational trophoblastic neoplasia (GTN) with low and high risk and evaluation of their first pregnancy outcome. Int J Hematol Stem Cell Res. 2018;12(4):291–7.

Silva Ferreira I, Mendes Lima SK, Alves Moralles Dias J, de Souza Gomes LF, Carvalho Fernandes AF, Kelve de Castro Damasceno A, et al. Gestational trophoblastic disease: An analysis focused on social determinants of health. Int Arch Med. 2016;9(189):1–8.

Gockley AA, Joseph NT, Melamed A, Sun SY, Goodwin B, Bernstein M, et al. Effect of race/ethnicity on clinical presentation and risk of gestational trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral center. Am J Obstet Gynecol. 2016;334.e1-334.e6.

Al Riyami N, Al Riyami M, Al Hajri AT, Al Saidi S, Salman B, Al Kalbani M. Gestational trophoblastic disease at Sultan Qaboos University Hospital: Prevalence, risk factors, histological features, sonographic findings, and outcomes. Oman Med J. 2019;34(3):200–4.

Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynecol Obstet. 2018;143(Suppl. 2):79–85.

Aminimoghaddam S, Maghsoudnia A. Unusual presentation of invasive mole: A case report. J Reprod Infertil. 2017;18(1):205–9.

Soper JT. Gestational trophoblastic disease: current evaluation and management. Obstet Gynecol. 2021;137(2):355–70.

Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Sook Chon H, et al. Gestational trophoblastic neoplasia version 2.2019. JNCCN J Natl Compr Cancer Netw. 2019;17(11):1374–91.

Mirji S, Patel B, Desai A, Patel S, Mankad M, Dave P. Role of surgery in the management of gestational trophoblastic neoplasia. Indian J Gynecol Oncol. 2019;17(22):1–7.

DOI: http://dx.doi.org/10.24198/obgynia/v5n2.380